New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
05:20 EDTINOInovio initiates cervical cancer clinical trial
Inovio Pharmaceuticals announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity, clinical responses and disease-free survival of its DNA immunotherapy product, INO-3112, in treating human papillomavirus-associated cervical cancer. INO-3112 is a combination of Inovio's immunotherapy product, VGX-3100, and its immune activator expressing interleukin-12. VGX-3100 is currently being evaluated in a randomized phase II efficacy trial for the treatment of high grade cervical dysplasia.
News For INO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 25, 2015
07:16 EDTINOPiper Jaffray and the Alliance for Regenerative Medicine co-host conference
3rd Annual Regenerative Medicine Investor Day is being held in New York on March 25 with webcasted company presentations to begin at 8 am; not all company presentations may be webcasted. Webcast Link
March 23, 2015
06:53 EDTINOInovio to host investor day
Subscribe for More Information
March 16, 2015
08:14 EDTINOInovio, academic collaborators receives $16M HIV grant from NIAID
Subscribe for More Information
06:35 EDTINOInovio reports Q4 EPS (12c), consensus (10c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use